Thesis
Approved liver-directed chemotherapy turns profitable; mCRC and mBC expansions determine whether uveal melanoma niche scales to durable franchise
Delcath reached full-year profitability in 2025 on HEPZATO, an FDA-approved isolated hepatic perfusion system for uveal melanoma liver metastases, with revenue growing 129% to $85.2M. Whether the thesis scales turns on Phase 2 readouts in liver-dominant mCRC and mBC converting a narrow oncology niche into a broader liver-directed platform. The primary risk is that both expansions rely on single-arm or early-phase data in indications where systemic agents continue to evolve, creating approval-path and adoption uncertainty without randomized support.
Focus
HEPZATO commercial ramp: raised FY2026 guidance to $104M–$108M with 31 active centers
Q3–Q4 2026
Bull
If Delcath continues adding treatment centers beyond 31 and procedure volume growth remains at or above the guided 28% rate, the company could meet or beat the $104M–$108M guidance range and generate positive adjusted EBITDA, establishing a self-funding commercial-stage biotech narrative. Sustained 90% gross margins combined with operating leverage would further reinforce a path to meaningful net profitability in 2026, compressing the valuation multiple investors apply to the revenue base.
Bear
Treatment center expansion could slow if procedural complexity, reimbursement friction, or hospital capacity constraints limit new site activations, causing volume growth to decelerate below the guided 28% and potentially requiring a guidance cut. Additionally, competition for the uveal melanoma indication from IDEAYA Biosciences' darovasertib — a targeted systemic therapy that could reduce referrals for hepatic perfusion — may pressure the addressable patient pool in HEPZATO's only FDA-approved indication.
Unlock the full thesis for DCTH.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.